Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28
Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.
A big investment research team just started following Pacira, a medicine company, and said the stock will probably do about as well as the overall market. This helps investors understand what experts think, but it doesn't tell us whether things are getting better or worse for the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.